First-line treatment of chronic myeloid leukaemia.

about

First-line treatment of chronic myeloid leukaemia.

Item

http://www.wikidata.org/entity/Q36612527

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

First-line treatment of chronic myeloid leukaemia.

@ast

First-line treatment of chronic myeloid leukaemia.

@en

type

Item

label

First-line treatment of chronic myeloid leukaemia.

@ast

First-line treatment of chronic myeloid leukaemia.

@en

prefLabel

First-line treatment of chronic myeloid leukaemia.

@ast

First-line treatment of chronic myeloid leukaemia.

@en

P1476

First-line treatment of chronic myeloid leukaemia.

@en

P2093

Michael O'Dwyer

http://www.w3.org/2001/XMLSchema#string

P2860

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.

Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia.

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy

BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.

P304

15-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2040620710387981

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236106925

http://www.w3.org/2001/XMLSchema#string

P698

23556068

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

P932

3573384

http://www.w3.org/2001/XMLSchema#string